We are analyzing https://link.springer.com/article/10.1007/s12672-025-02519-x.

Title:
BEND4: a novel prognostic biomarker in diffuse large B-cell lymphoma | Discover Oncology
Description:
Background BEN domain-containing protein 4 (BEND4) is implicated in various cancer-related processes, but its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. This study examined BEND4’s impact on DLBCL prognosis through bioinformatics analysis. Methods BEND4 expression was analyzed across the cancer cell line encyclopedia (CCLE), human protein atlas (HPA), and the cancer genome atlas (TCGA) databases. Associations between BEND4 expression and survival outcomes, prognosis, and immune infiltration levels of DLBCL were evaluated via TCGA. Gene set enrichment analysis (GSEA) identified potential BEND4 biological functions. The predictive value of BEND4 and related genes for DLBCL mortality was assessed using time-dependent receiver operating characteristic curve (ROC) analysis. Findings were validated through qRT-PCR and cell proliferation assays. Results BEND4 was overexpressed at mRNA and protein levels in DLBCL. High BEND4 expression correlated with shorter survival, higher disease-specific mortality, and poor prognosis, emerging as an independent risk factor. GSEA revealed associations between BEND4 and chromatin remodeling, immune response, epigenetic regulation, and signal transduction. Immune infiltration analysis showed BEND4 expression was inversely correlated with eosinophils, cytotoxic cells, and Tgd cells infiltration. ROC analysis confirmed BEND4 and related genes as key predictors of DLBCL mortality at 1, 3, and 5 years. In vitro, BEND4 inhibition did not alter Riva cells proliferation but enhanced sensitivity of Riva cells to chemotherapy, including doxorubicin. Conclusion Elevated BEND4 levels were linked to poor prognosis and chemoresistance in DLBCL, potentially due to transcriptional regulation and immune suppression roles. BEND4 may represent a viable therapeutic target in DLBCL.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Photography

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

bend, expression, dlbcl, cell, analysis, cells, pubmed, article, fig, immune, genes, cancer, google, scholar, cas, gene, correlated, high, lymphoma, levels, tumor, infiltration, riva, dna, central, protein, survival, bcell, top, significantly, data, tcga, diffuse, large, proliferation, risk, lines, pathways, negatively, prognostic, wang, ben, prognosis, gsea, mortality, chromatin, normal, low, functional, positively,

Topics {✒️}

immune-regulation-related pathways—bcr activation activates cpg-island-regulated genes b-cell tumor subtypes identifying high-risk biomarkers methylation-sensitive dna-binding protein cell receptor complex poor inhibitory effect time-dependent roc analysis article download pdf kaplan–meier curves comparing immune cell markers dna viral proteins gov/projects/tcga-dlbc sequence-specific dna binding lymphoma research center diffuse large potential chemo-sensitization effect mantle cell lymphoma genotype-tissue expression project higher disease-specific mortality bend4-related genes mapped genome-wide dna methylation independent risk factor rituximab-based chemotherapy cures protein–protein interaction network high-expression group showed prognostic biomarkers fei dong designed chromatin boundary factor transcription factor banp immune cell infiltration including burkitt lymphoma experimental validation human-sirna-negative control multivariate cox analysis gene markers cd38 significantly increased sensitivity full access single-cell resolution single-cell level germ cell differentiation privacy choices/manage cookies primary therapy outcome cell lymphoma cell counting kit-8 gene editing technology le calvez-kelm plasma cell myeloma gene promoter regions immune cell types

Questions {❓}

Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
New insights into first-line therapy in diffuse large B-cell lymphoma: are we improving outcomes?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:BEND4: a novel prognostic biomarker in diffuse large B-cell lymphoma
         description:BEN domain-containing protein 4 (BEND4) is implicated in various cancer-related processes, but its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. This study examined BEND4’s impact on DLBCL prognosis through bioinformatics analysis. BEND4 expression was analyzed across the cancer cell line encyclopedia (CCLE), human protein atlas (HPA), and the cancer genome atlas (TCGA) databases. Associations between BEND4 expression and survival outcomes, prognosis, and immune infiltration levels of DLBCL were evaluated via TCGA. Gene set enrichment analysis (GSEA) identified potential BEND4 biological functions. The predictive value of BEND4 and related genes for DLBCL mortality was assessed using time-dependent receiver operating characteristic curve (ROC) analysis. Findings were validated through qRT-PCR and cell proliferation assays. BEND4 was overexpressed at mRNA and protein levels in DLBCL. High BEND4 expression correlated with shorter survival, higher disease-specific mortality, and poor prognosis, emerging as an independent risk factor. GSEA revealed associations between BEND4 and chromatin remodeling, immune response, epigenetic regulation, and signal transduction. Immune infiltration analysis showed BEND4 expression was inversely correlated with eosinophils, cytotoxic cells, and Tgd cells infiltration. ROC analysis confirmed BEND4 and related genes as key predictors of DLBCL mortality at 1, 3, and 5 years. In vitro, BEND4 inhibition did not alter Riva cells proliferation but enhanced sensitivity of Riva cells to chemotherapy, including doxorubicin. Elevated BEND4 levels were linked to poor prognosis and chemoresistance in DLBCL, potentially due to transcriptional regulation and immune suppression roles. BEND4 may represent a viable therapeutic target in DLBCL.
         datePublished:2025-05-06T00:00:00Z
         dateModified:2025-05-06T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by-nc-nd/4.0/
         sameAs:https://doi.org/10.1007/s12672-025-02519-x
         keywords:
            BEND4
            Diffuse large B-cell lymphoma
            TCGA
            Biomarker
            Prognosis
            Immune infiltration
            Oncology
            Cancer Research
            Surgical Oncology
            Molecular Medicine
            Radiotherapy
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig8_HTML.png
         isPartOf:
            name:Discover Oncology
            issn:
               2730-6011
            volumeNumber:16
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yanfang Wang
               affiliation:
                     name:Peking University Third Hospital
                     address:
                        name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhenhao Zhang
               affiliation:
                     name:Peking University Third Hospital
                     address:
                        name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lianyong Xi
               affiliation:
                     name:Peking University Third Hospital
                     address:
                        name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hua Wang
               affiliation:
                     name:Peking University Third Hospital
                     address:
                        name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fei Dong
               affiliation:
                     name:Peking University Third Hospital
                     address:
                        name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:BEND4: a novel prognostic biomarker in diffuse large B-cell lymphoma
      description:BEN domain-containing protein 4 (BEND4) is implicated in various cancer-related processes, but its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. This study examined BEND4’s impact on DLBCL prognosis through bioinformatics analysis. BEND4 expression was analyzed across the cancer cell line encyclopedia (CCLE), human protein atlas (HPA), and the cancer genome atlas (TCGA) databases. Associations between BEND4 expression and survival outcomes, prognosis, and immune infiltration levels of DLBCL were evaluated via TCGA. Gene set enrichment analysis (GSEA) identified potential BEND4 biological functions. The predictive value of BEND4 and related genes for DLBCL mortality was assessed using time-dependent receiver operating characteristic curve (ROC) analysis. Findings were validated through qRT-PCR and cell proliferation assays. BEND4 was overexpressed at mRNA and protein levels in DLBCL. High BEND4 expression correlated with shorter survival, higher disease-specific mortality, and poor prognosis, emerging as an independent risk factor. GSEA revealed associations between BEND4 and chromatin remodeling, immune response, epigenetic regulation, and signal transduction. Immune infiltration analysis showed BEND4 expression was inversely correlated with eosinophils, cytotoxic cells, and Tgd cells infiltration. ROC analysis confirmed BEND4 and related genes as key predictors of DLBCL mortality at 1, 3, and 5 years. In vitro, BEND4 inhibition did not alter Riva cells proliferation but enhanced sensitivity of Riva cells to chemotherapy, including doxorubicin. Elevated BEND4 levels were linked to poor prognosis and chemoresistance in DLBCL, potentially due to transcriptional regulation and immune suppression roles. BEND4 may represent a viable therapeutic target in DLBCL.
      datePublished:2025-05-06T00:00:00Z
      dateModified:2025-05-06T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by-nc-nd/4.0/
      sameAs:https://doi.org/10.1007/s12672-025-02519-x
      keywords:
         BEND4
         Diffuse large B-cell lymphoma
         TCGA
         Biomarker
         Prognosis
         Immune infiltration
         Oncology
         Cancer Research
         Surgical Oncology
         Molecular Medicine
         Radiotherapy
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-02519-x/MediaObjects/12672_2025_2519_Fig8_HTML.png
      isPartOf:
         name:Discover Oncology
         issn:
            2730-6011
         volumeNumber:16
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yanfang Wang
            affiliation:
                  name:Peking University Third Hospital
                  address:
                     name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhenhao Zhang
            affiliation:
                  name:Peking University Third Hospital
                  address:
                     name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lianyong Xi
            affiliation:
                  name:Peking University Third Hospital
                  address:
                     name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hua Wang
            affiliation:
                  name:Peking University Third Hospital
                  address:
                     name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fei Dong
            affiliation:
                  name:Peking University Third Hospital
                  address:
                     name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Discover Oncology
      issn:
         2730-6011
      volumeNumber:16
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Peking University Third Hospital
      address:
         name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
         type:PostalAddress
      name:Peking University Third Hospital
      address:
         name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
         type:PostalAddress
      name:Peking University Third Hospital
      address:
         name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
         type:PostalAddress
      name:Peking University Third Hospital
      address:
         name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
         type:PostalAddress
      name:Peking University Third Hospital
      address:
         name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yanfang Wang
      affiliation:
            name:Peking University Third Hospital
            address:
               name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Zhenhao Zhang
      affiliation:
            name:Peking University Third Hospital
            address:
               name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Lianyong Xi
      affiliation:
            name:Peking University Third Hospital
            address:
               name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Hua Wang
      affiliation:
            name:Peking University Third Hospital
            address:
               name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Fei Dong
      affiliation:
            name:Peking University Third Hospital
            address:
               name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
      name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
      name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
      name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
      name:Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China

External Links {🔗}(163)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.02s.

LINK . SPRINGER . COM {}